SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).

The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.

Earlier in November, the Chalmers University of Technology in Sweden published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics.

Biotech company Cytomos has announced this month that it has raised £5m to scale up the production of its unique cell analysis technology.

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD complete.

Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it.

French start-up Bioptimus has announced that its H-optimus-o biology reference artificial intelligence (AI) foundation model has been wholly integrated into Proscia’s Concentriq embeddings software platform, with the aim of enabling quicker and more efficient breakthroughs in ai development for therapeutic research.

Hosted again in Barcelona, Spain, the Immunoskin conference ran from 26-27 October and brought together leading experts in dermatological conditions and treatments.

Liveo Research, a leading primary packaging manufacturer, has had the EcoVadis rating of its Singapore site increased from gold to platinum. This means that the pharma packaging site is now rated in the top 1% of the 100,000 companies evaluated by ecovadis in its annual global surveys.

In late October, HUTCHMED’s partner Takeda will pay a milestone payment of $20m as the result of over $200m worth of sales for Fruzaqla (fruquintinib), which treats metastatic colorectal cancer (CRC).

Running from 26-28 November 2024, the largest pharma event in India is expected to have a record attendance of delegates from more than 150 countries, with over 2,000 exhibitors also expected.

Announced by PacBio, known for developing sequencing solutions, SPRQ has the potential to significantly reduce the cost of sequencing genomes.